{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:34:37Z","timestamp":1762324477904,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T00:00:00Z","timestamp":1555545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001029","name":"Department of Defence, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001029","id-type":"DOI","asserted-by":"publisher"}]},{"name":"School of Public Health and Social Work"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12936-019-2774-2","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T09:07:39Z","timestamp":1555578459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor"],"prefix":"10.1186","volume":"18","author":[{"given":"Nanhua","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Dowd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Gatton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"Auliff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Edstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,18]]},"reference":[{"key":"2774_CR1","unstructured":"WHO. World malaria report 2017. Geneva: World Health Organization. 2017. http:\/\/www.who.int\/malaria ."},{"key":"2774_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4269\/ajtmh.16-0141","volume":"95","author":"RE Howes","year":"2016","unstructured":"Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, et al. Global epidemiology of Plasmodium vivax. Am J Trop Med Hyg. 2016;95:15\u201334.","journal-title":"Am J Trop Med Hyg"},{"key":"2774_CR3","doi-asserted-by":"publisher","first-page":"e3413","DOI":"10.1371\/journal.pntd.0003413","volume":"9","author":"Q Cheng","year":"2015","unstructured":"Cheng Q, Cunningham J, Gatton ML. Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors. PLoS Negl Trop Dis. 2015;9:e3413.","journal-title":"PLoS Negl Trop Dis"},{"key":"2774_CR4","doi-asserted-by":"publisher","first-page":"e1001891","DOI":"10.1371\/journal.pmed.1001891","volume":"12","author":"LJ Robinson","year":"2015","unstructured":"Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li W, Suen CS, et al. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med. 2015;12:e1001891.","journal-title":"PLoS Med"},{"key":"2774_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12936-017-1925-6","volume":"16","author":"J Recht","year":"2017","unstructured":"Recht J, Siqueira AM, Monteiro WM, Herrera SM, Herrera S, Lacerda MVG. Malaria in Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination. Malar J. 2017;16:273.","journal-title":"Malar J."},{"key":"2774_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5365\/wpsar.2014.5.3.002","volume":"5","author":"H Oloifana-Polosovai","year":"2014","unstructured":"Oloifana-Polosovai H, Gwala J, Harrington H, Massey PD, Ribeyro E, Flores A, et al. A marked decline in the incidence of malaria in a remote region of Malaita, Solomon Islands, 2008 to 2013. Western Pac Surveill Response J. 2014;5:30\u20139.","journal-title":"Western Pac Surveill Response J."},{"key":"2774_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/1475-2875-13-385","volume":"13","author":"RJ Maude","year":"2014","unstructured":"Maude RJ, Nguon C, Ly P, Bunkea T, Ngor P, Canavati de la Torre SE, et al. Spatial and temporal epidemiology of clinical malaria in Cambodia 2004\u20132013. Malar J. 2014;13:385.","journal-title":"Malar J."},{"key":"2774_CR8","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015. http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241549127\/en ."},{"key":"2774_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1475-2875-9-308","volume":"9","author":"R Takeuchi","year":"2010","unstructured":"Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, et al. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai\u2013Myanmar border. Malar J. 2010;9:308.","journal-title":"Malar J."},{"key":"2774_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3329\/jhpn.v27i1.3313","volume":"27","author":"N Khantikul","year":"2009","unstructured":"Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MA, Suwonkerd W. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J Health Popul Nutr. 2009;27:4\u201313.","journal-title":"J Health Popul Nutr."},{"key":"2774_CR11","first-page":"9","volume":"42","author":"W Maneeboonyang","year":"2011","unstructured":"Maneeboonyang W, Lawpoolsri S, Puangsa-Art S, Yimsamran S, Thanyavanich N, Wuthisen P, et al. Directly observed therapy with primaquine to reduce the recurrence rate of Plasmodium vivax infection along the Thai\u2013Myanmar border. Southeast Asian J Trop Med Public Health. 2011;42:9\u201318.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"2774_CR12","doi-asserted-by":"publisher","first-page":"e1002299","DOI":"10.1371\/journal.pmed.1002299","volume":"14","author":"T Abreha","year":"2017","unstructured":"Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether\u2013lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14:e1002299.","journal-title":"PLoS Med."},{"key":"2774_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4269\/ajtmh.1996.55.243","volume":"55","author":"WE Collins","year":"1996","unstructured":"Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg. 1996;55:243\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"2774_CR14","volume-title":"Guidelines for the treatment of malaria","author":"W Ho","year":"2006","unstructured":"Ho W. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006."},{"key":"2774_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.inhe.2010.03.001","volume":"2","author":"NJ Elmes","year":"2010","unstructured":"Elmes NJ. Malaria notifications in the Australian Defence Force from 1998 to 2007. Int Health. 2010;2:130\u20135.","journal-title":"Int Health."},{"key":"2774_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/1475-2875-11-280","volume":"11","author":"GK John","year":"2012","unstructured":"John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11:280.","journal-title":"Malar J."},{"key":"2774_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/1475-2875-11-259","volume":"11","author":"BS Pybus","year":"2012","unstructured":"Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J. 2012;11:259.","journal-title":"Malar J."},{"key":"2774_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1475-2875-12-212","volume":"12","author":"BS Pybus","year":"2013","unstructured":"Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013;12:212.","journal-title":"Malar J."},{"key":"2774_CR19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","volume":"17","author":"J Sistonen","year":"2007","unstructured":"Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93\u2013101.","journal-title":"Pharmacogenet Genomics"},{"key":"2774_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234\u201342.","journal-title":"Clin Pharmacol Ther"},{"key":"2774_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.690","volume":"102","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017;102:688\u2013700.","journal-title":"Clin Pharmacol Ther"},{"key":"2774_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1517\/14622416.3.2.229","volume":"3","author":"LD Bradford","year":"2002","unstructured":"Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229\u201343.","journal-title":"Pharmacogenomics."},{"key":"2774_CR23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/dna.1991.10.545","volume":"10","author":"F Broly","year":"1991","unstructured":"Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine\/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991;10:545\u201358.","journal-title":"DNA Cell Biol"},{"key":"2774_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00008571-199804000-00010","volume":"8","author":"C Sachse","year":"1998","unstructured":"Sachse C, Brockmoller J, Hildebrand M, Muller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics. 1998;8:181\u20135.","journal-title":"Pharmacogenetics."},{"key":"2774_CR25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJMc1301936","volume":"369","author":"JW Bennett","year":"2013","unstructured":"Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369:1381\u20132.","journal-title":"N Engl J Med"},{"key":"2774_CR26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/1475-2875-13-488","volume":"13","author":"RJ Ingram","year":"2014","unstructured":"Ingram RJ, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J. 2014;13:488.","journal-title":"Malar J."},{"key":"2774_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12936-017-2139-7","volume":"17","author":"LW Brasil","year":"2018","unstructured":"Brasil LW, Rodrigues-Soares F, Santoro AB, Almeida ACG, Kuhn A, Ramasawmy R, et al. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. Malar J. 2018;17:57.","journal-title":"Malar J."},{"key":"2774_CR28","doi-asserted-by":"publisher","first-page":"e0160172","DOI":"10.1371\/journal.pone.0160172","volume":"11","author":"AC Silvino","year":"2016","unstructured":"Silvino AC, Costa GL, Araujo FC, Ascher DB, Pires DE, Fontes CJ, et al. Variation in human cytochrome P-450 drug-metabolism genes: a gateway to the understanding of Plasmodium vivax relapses. PLoS ONE. 2016;11:e0160172.","journal-title":"PLoS ONE"},{"key":"2774_CR29","doi-asserted-by":"publisher","first-page":"e181449","DOI":"10.1001\/jamanetworkopen.2018.1449","volume":"1","author":"JK Baird","year":"2018","unstructured":"Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, et al. Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria. JAMA Network Open. 2018;1:e181449.","journal-title":"JAMA Network Open."},{"key":"2774_CR30","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3201\/eid1905.121852","volume":"19","author":"AT Bright","year":"2013","unstructured":"Bright AT, Alenazi T, Shokoples S, Tarning J, Paganotti GM, White NJ, et al. Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. Emerg Infect Dis. 2013;19:802\u20135.","journal-title":"Emerg Infect Dis"},{"key":"2774_CR31","first-page":"56","volume":"61","author":"MD Edstein","year":"2001","unstructured":"Edstein MD, Walsh DS, Eamsila C, Sasiprapha T, Nasveld PE, Kitchener S, et al. Malaria prophylaxis\/radical cure: recent experiences of the Australian Defence Force. Med Trop (Mars). 2001;61:56\u20138.","journal-title":"Med Trop (Mars)."},{"key":"2774_CR32","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1086\/512242","volume":"195","author":"N Chen","year":"2007","unstructured":"Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis. 2007;195:934\u201341.","journal-title":"J Infect Dis"},{"key":"2774_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19:69\u201376.","journal-title":"Genet Med."},{"key":"2774_CR34","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/tpj.2014.27","volume":"14","author":"H Fang","year":"2014","unstructured":"Fang H, Liu X, Ramirez J, Choudhury N, Kubo M, Im HK, et al. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 2014;14:564\u201372.","journal-title":"Pharmacogenomics J."},{"key":"2774_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00702-014-1273-4","volume":"122","author":"F Gressier","year":"2015","unstructured":"Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E. Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors. J Neural Transm (Vienna). 2015;122:35\u201342.","journal-title":"J Neural Transm (Vienna)."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-019-2774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-019-2774-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-019-2774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T06:29:40Z","timestamp":1663309780000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-019-2774-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,18]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2774"],"URL":"https:\/\/doi.org\/10.1186\/s12936-019-2774-2","relation":{},"ISSN":["1475-2875"],"issn-type":[{"type":"electronic","value":"1475-2875"}],"subject":[],"published":{"date-parts":[[2019,4,18]]},"assertion":[{"value":"16 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"140"}}